公开(公告)号：US20240124466A1

公开(公告)日：2024-04-18

申请号：US18256995

申请日：2021-12-10

申请人： VOVA IDA THERAPEUTICS, INC. ,  SCRIPPS RESEARCH INSTITUTE, THE

发明人： Thomas D. BANNISTER ,  Corinne LASMEZAS ,  Minghai ZHOU ,  Nicole KENNEDY

IPC分类号： C07D487/04 ,  C07D213/34 ,  C07D213/61 ,  C07D213/74 ,  C07D231/12 ,  C07D231/56 ,  C07D233/64 ,  C07D237/30 ,  C07D249/08 ,  C07D271/06 ,  C07D285/08 ,  C07D333/18 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D491/113 ,  C07D498/08

CPC分类号： C07D487/04 ,  C07D213/34 ,  C07D213/61 ,  C07D213/74 ,  C07D231/12 ,  C07D231/56 ,  C07D233/64 ,  C07D237/30 ,  C07D249/08 ,  C07D271/06 ,  C07D285/08 ,  C07D333/18 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/048 ,  C07D491/107 ,  C07D491/113 ,  C07D498/08

摘要： Provided are, inter alia, compounds having a structure of Formula (X), or a pharmaceutically acceptable salt thereof composition including the same and methods of use. Ring A, L1, L2, W, R2A, R2B, and R10 are as described herein.

公开(公告)号：US11866431B2

公开(公告)日：2024-01-09

申请号：US17291765

申请日：2019-11-07

申请人： Vivace Therapeutics, Inc.

发明人： Andrei W. Konradi ,  Tracy Tzu-Ling Tang Lin

IPC分类号： C07D471/04 ,  C07C233/65 ,  C07C233/69 ,  C07C235/66 ,  C07C237/48 ,  C07C271/16 ,  C07C307/06 ,  C07C311/16 ,  C07C311/51 ,  C07C317/32 ,  C07D205/04 ,  C07D213/40 ,  C07D213/61 ,  C07D213/73 ,  C07D213/74 ,  C07D213/84 ,  C07D215/48 ,  C07D215/54 ,  C07D217/18 ,  C07D231/56 ,  C07D233/64 ,  C07D235/06 ,  C07D239/26 ,  C07D239/28 ,  C07D241/12 ,  C07D241/44 ,  C07D257/04 ,  C07D261/12 ,  C07D263/56 ,  C07D271/12 ,  C07D277/82 ,  C07D285/08 ,  C07D295/13 ,  C07D305/06 ,  C07D307/22 ,  C07D333/58 ,  C07D401/12 ,  C07D413/12

CPC分类号： C07D471/04 ,  C07C233/65 ,  C07C233/69 ,  C07C235/66 ,  C07C237/48 ,  C07C271/16 ,  C07C307/06 ,  C07C311/16 ,  C07C311/51 ,  C07C317/32 ,  C07D205/04 ,  C07D213/40 ,  C07D213/61 ,  C07D213/73 ,  C07D213/74 ,  C07D213/84 ,  C07D215/48 ,  C07D215/54 ,  C07D217/18 ,  C07D231/56 ,  C07D233/64 ,  C07D235/06 ,  C07D239/26 ,  C07D239/28 ,  C07D241/12 ,  C07D241/44 ,  C07D257/04 ,  C07D261/12 ,  C07D263/56 ,  C07D271/12 ,  C07D277/82 ,  C07D285/08 ,  C07D295/13 ,  C07D305/06 ,  C07D307/22 ,  C07D333/58 ,  C07D401/12 ,  C07D413/12

摘要： Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

公开(公告)号：US20230150931A1

公开(公告)日：2023-05-18

申请号：US17944821

申请日：2022-09-14

申请人： Novius Therapeutics, LLC

发明人： Liraz Levi ,  Tej Pareek ,  Elizabeth Meyers ,  Seunghwan Lim ,  William J. Greenlee ,  Seong-Jin Kim

IPC分类号： C07C323/61 ,  C07C235/74 ,  C07D333/40 ,  C07D307/24 ,  C07C325/02 ,  C07C257/06 ,  C07D263/44 ,  C07D271/07 ,  C07D285/08 ,  C07D291/04 ,  C07C311/13 ,  A61P35/04

CPC分类号： C07C323/61 ,  C07C235/74 ,  C07D333/40 ,  C07D307/24 ,  C07C325/02 ,  C07C257/06 ,  C07D263/44 ,  C07D271/07 ,  C07D285/08 ,  C07D291/04 ,  C07C311/13 ,  A61P35/04

摘要： Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

公开(公告)号：US20230061429A1

公开(公告)日：2023-03-02

申请号：US17291765

申请日：2019-11-07

申请人： Vivace Therapeutics, Inc.

发明人： Andrei W. KONRADI ,  Tracy Tzu-Ling Tang LIN

IPC分类号： C07D471/04 ,  C07C311/16 ,  C07D295/13 ,  C07D233/64 ,  C07D261/12 ,  C07C235/66 ,  C07D213/61 ,  C07D217/18 ,  C07D307/22 ,  C07D413/12 ,  C07C311/51 ,  C07D231/56 ,  C07D401/12 ,  C07D239/26 ,  C07D241/44 ,  C07D271/12 ,  C07D285/08 ,  C07C233/65 ,  C07C237/48 ,  C07D213/74 ,  C07D215/54 ,  C07D333/58 ,  C07C271/16 ,  C07D215/48 ,  C07D239/28 ,  C07D257/04 ,  C07D277/82 ,  C07C307/06 ,  C07D213/40 ,  C07D213/84 ,  C07D305/06 ,  C07C233/69 ,  C07C317/32 ,  C07D205/04 ,  C07D235/06 ,  C07D241/12 ,  C07D263/56 ,  C07D213/73

摘要： Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

公开(公告)号：US11447453B2

公开(公告)日：2022-09-20

申请号：US16817209

申请日：2020-03-12

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Nicholas David Peter Cosford ,  Dhanya Raveendra-Panickar ,  Douglas J. Sheffler ,  John Howard Hutchinson ,  Reto Andreas Gadient

IPC分类号： C07D277/20 ,  C07D285/08 ,  C07D249/08 ,  A61K31/426 ,  A61K31/433 ,  A61K31/4196 ,  A61P25/00 ,  C07D243/14 ,  A61K31/427 ,  C07D217/06 ,  C07D417/04 ,  C07D403/12 ,  C07D233/54 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D405/04 ,  C07D239/26 ,  C07D409/04 ,  C07D243/12 ,  C07D271/06 ,  C07D275/02 ,  C07D277/30 ,  A61K31/505 ,  A61K31/506 ,  C07D231/12 ,  C07D233/64 ,  C07D261/08 ,  C07D263/32 ,  C07D277/26 ,  C07D307/38 ,  C07D333/24 ,  C07D401/14 ,  C07D405/10 ,  C07D409/02 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

摘要： Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20210276964A1

公开(公告)日：2021-09-09

申请号：US17066397

申请日：2020-10-08

申请人： CEDARS-SINAI MEDICAL CENTER

发明人： Mouad Edderkaoui ,  Ramachandran Murali ,  Stephen Pandol

IPC分类号： C07D285/08 ,  C07D271/10 ,  C07D271/107 ,  A61K31/433 ,  A61K45/06 ,  A61K31/167 ,  A61K31/4245 ,  C07D271/113

摘要： The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

公开(公告)号：US20210238127A1

公开(公告)日：2021-08-05

申请号：US17233488

申请日：2021-04-18

申请人： National Institute of Biological Sciences, Beijing

发明人： Niu Huang ,  Shiming Peng

IPC分类号： C07C255/34 ,  A61P25/28 ,  A61P3/04 ,  C07D277/30 ,  C07D277/46 ,  C07D213/57 ,  C07D237/14 ,  C07D239/36 ,  C07D241/24 ,  C07D251/16 ,  C07D241/52 ,  C07D471/04 ,  C07D213/80 ,  C07D241/20 ,  C07D285/08 ,  C07D295/185 ,  C07D241/12 ,  C07D249/08 ,  C07D261/12 ,  C07D239/42 ,  C07D215/233 ,  C07D277/56 ,  C07D249/12 ,  C07D211/82 ,  C07D487/04 ,  C07D235/08 ,  C07D231/14 ,  C07D209/08 ,  C07D239/26 ,  C07D233/56 ,  C07D277/24 ,  C07D261/08 ,  C07D307/46 ,  C07D257/04 ,  C07D213/75 ,  C07D277/64 ,  C07C255/43

摘要： The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

公开(公告)号：US20210171537A1

公开(公告)日：2021-06-10

申请号：US16805895

申请日：2020-03-02

申请人： Xenon Pharmaceuticals Inc.

发明人： Jean-Christophe Andrez ,  David Earl Bogucki ,  Kristen Nicole Burford ,  Sultan Chowdhury ,  Charles Jay Cohen ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Robert Joseph Devita ,  James Roy Empfield ,  Thilo Focken ,  Michael Edward Grimwood ,  Syed Abid Hasan ,  Qi Jia ,  James Philip Johnson, JR. ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D491/107 ,  C07D493/10 ,  C07D237/20 ,  C07D213/76 ,  C07D239/69 ,  C07D261/16 ,  C07D263/50 ,  C07D275/03 ,  C07D277/52 ,  C07D285/08 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/10 ,  C07D417/14 ,  C07D451/06

摘要： This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20210163467A1

公开(公告)日：2021-06-03

申请号：US17046750

申请日：2019-04-09

申请人： Neuropore Therapies, Inc.

发明人： Emily M. STOCKING ,  Wolfgang J. WRASIDLO

IPC分类号： C07D417/12 ,  C07D285/135 ,  C07D285/08 ,  C07D417/04

摘要： The present disclosure relates to thiazole- or diathiazole-substituted aryl and heteroaryl compounds (I), pharmaceutical compositions containing them, and methods of using them, including treatment of disorders or disease related to regulation of the Vps34/PI3K III signaling pathway.

公开(公告)号：US20200347021A1

公开(公告)日：2020-11-05

申请号：US16817209

申请日：2020-03-12

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Nicholas David Peter COSFORD ,  Dhanya RAVEENDRA-PANICKAR ,  Douglas J. SHEFFLER ,  John Howard HUTCHINSON ,  Reto Andreas GADIENT

IPC分类号： C07D243/14 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  C07D217/06 ,  C07D417/04 ,  C07D249/08 ,  C07D277/20 ,  C07D285/08 ,  C07D403/12 ,  C07D233/54 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D405/04 ,  C07D239/26 ,  C07D409/04 ,  C07D243/12 ,  C07D271/06 ,  C07D275/02 ,  C07D277/30 ,  A61K31/505 ,  A61K31/506 ,  C07D231/12 ,  C07D233/64 ,  C07D261/08 ,  C07D263/32 ,  C07D277/26 ,  C07D307/38 ,  C07D333/24 ,  C07D401/14 ,  C07D405/10 ,  C07D409/02 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  A61P25/00

摘要： Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.